As expected, using PMA to stimulate PBMCs from active SLE resulted in a significant upregulation of CD40L and CTLA4, whereas this upregulation is not observed in PBMCs pretreated with chemical inhibitor of PYK2 kinase activity (Figure 5C). The gene discussed is PTK2B; the disease is systemic lupus erythematosus.